

Johnson & Johnson

**CORPORATE HEADQUARTERS
PATENT LAW DEPARTMENT
ONE JOHNSON & JOHNSON PLAZA
NEW BRUNSWICK, NEW JERSEY 08933**

FACSIMILE TRANSMISSION COVER SHEET

TO: Examiner A.A. Mohamed/GAU 1653

COMPANY: UNITED STATES PATENT & TRADEMARK OFFICE COUNTRY: U.S.A.

FACSIMILE NUMBER: 703-872-9306

FROM: Hal B. Woodrow

TELEPHONE NO.: 732-524-2976

ROOM NO.: 3231

DATE: October 23, 2003

FACSIMILE NUMBER: 732-524-5889

NUMBER OF PAGES INCLUDING THIS COVER SHEET: 3

**RECEIVED
CENTRAL FAX CENTER**

OCT 23 2003

**IF THERE IS A PROBLEM WITH THIS TRANSMISSION, PLEASE CALL
732-524-2820**

COMMENTS:

OFFICIAL

THIS MESSAGE IS INTENDED ONLY FOR THE INDIVIDUAL OR ENTITY TO WHICH IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL AND EXEMPT FROM DISCLOSURE UNDER APPLICABLE LAW. IF THE READER OF THIS MESSAGE IS NOT THE INTENDED RECIPIENT, OR THE EMPLOYEE OR AGENT RESPONSIBLE FOR DELIVERING THE MESSAGE SOLELY TO THE INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT ANY DISSEMINATION, DISTRIBUTION OR COPYING OF THIS COMMUNICATION IS STRICTLY PROHIBITED. IF YOU HAVE RECEIVED THIS COMMUNICATION IN ERROR, PLEASE NOTIFY US IMMEDIATELY BY TELEPHONE AND RETURN THE ORIGINAL MESSAGE TO US AT THE ABOVE ADDRESS VIA THE U.S. POSTAL SERVICE. THANK YOU.

Docket No. ORT-1238

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Zhang et al.
Appln. No. : 09/603,338
Filed : June 26, 2000
Title : NOVEL INDAZOLE PEPTIDOMIMETICS
AS THROMBIN RECEPTOR ANTAGONISTS
Art Unit : 1653
Examiner : A. A. Mohamed

I hereby certify that this correspondence is being facsimile transmitted
to the Patent and Trademark Office, Fax No. (703) 872-9306 on

October 23, 2003

(Date of facsimile transmission)

Hal B. Woodrow

(Name of applicant, assignee, or Registered Representative)

Hal B. Woodrow
(Signature)

October 23, 2003

(Date of signature)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

**RECEIVED
CENTRAL FAX CENTER**

OCT 23 2003

RESPONSE

Dear Sir:

This paper is responsive to the Office Action of 1 October 2003.

Remarks/Arguments begin on page 2 of this paper.

Serial No. 09/603,338

REMARKS

Applicants have elected Group III, claims 1-10, 23 and 19-22, drawn to a method of treating a condition mediated by thrombin receptor PAR-1.

Applicants hereby elect a single disclosed species compound 1, Benzenepropanamide, *N*-[(1*S*)-3-amino-1-[[[(phenylmethyl)amino] carbonyl]propyl]- α -[[[[1-(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1*H*-indazol-6-yl]amino]carbonyl]amino]-3,4-difluoro-, (α *S*). The chemical structure can be found in Table 1, on page 16 and on page 20 (bottom right corner).

Pursuant to the Examiner's request, applicant is providing a list of claims that would be readable on the elected species Compound 1. Claims 1-10, 23, and 19-22 read on Compound 1.

Applicant respectfully requests that a timely Notice of Allowance be issued in this case.

Respectfully submitted,

By: Hal Burt Woodrow

Hal B. Woodrow
Reg. No. 32,501

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003
(732) 524-2976
Dated: October 23, 2003

RECEIVED
CENTRAL FAX CENTER
OCT 23 2003

OFFICIAL